Analyst Conference Summaries

Biotechnology Investor Aids

Protalix BioTherapeutics

conference date: March 6, 2018 @ 5:30 AM Pacific Time

FDA Okays Phase 3 Study of PRX-102 for Fabry Disease [November 16, 2015]

Protalix Positive Preclinical Results for NASH [October 5, 2015]
Protalix Positive Interim Phase I/II Data for PRX-102 [Jan. 8, 2015]
Protalix: Undervalued Growth, Plus a Possible Biotech Breakthrough [Oct. 30, 2013 @ Seeking Alpha]

May 10, 2017
August 9, 2017
Nov. 8, 2017
March 6, 2018

Protalix BioTherapeutics (PLX) is a biotechnology company making proprietary recombinant therapeutic proteins with its ProCellEx plant cell based protein expression system.

Protalix does not currently hold quarterly conference calls for analysts. It is based in Israel, but registered in Florida and files with the SEC.

Protalix BioTherapeutics web site
Protalix investor relations page



More Analyst Conference Pages:



Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2013 William P. Meyers